Epioxa from Glaukos is the first epithelium-on corneal cross-linking treatment that has been FDA approved in the United ...
Epithelium-off CXL stabilizes keratoconus and improves vision over 5 years, with greatest benefits observed in patients ...
A pediatric subgroup from a pivotal phase 3 trial randomized 2:1 showed epithelium-on oxygen-enriched CXL improved Kmax at 6 ...
Keratoconus is a rare, progressive ophthalmic disorder characterized by changes to the cornea that result in significant vision loss. Epioxa is an oxygen-enriched, UV-bioactivated topical treatment ...
Glaukos Corporation GKOS recently announced the commercial availability of Epioxa, marking a significant milestone in its corneal health portfolio. The therapy stands out as the first FDA-approved, ...
Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare Disease “We are delighted to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results